Filing Flows › 8-K events › Microbot Medical
Microbot Medical: regulation fd disclosure
Form 8-K filed Oct 23, 2026 · items 7.01
FDA decisionsMicrobot Medical ® Attending Key Medical Conference to Engage with Decisionmakers as it Continues to Expand Presence Across the U.S.
What the filing says
Microbot Medical ® Attending Key Medical Conference to Engage with Decisionmakers as it Continues to Expand Presence Across the U.S. Opportunity to Connect with Hospital Administrators and Physicians to Foster Expanded Adoption of the LIBERTY System
Read the filing on SEC EDGAR →
Microbot Medical at a glance
Latest quarterQ2 2026
Revenue$241K
Operating marginn/m
IndustrySurgical & Medical Instruments & Apparatus
Microbot Medical, Q2 2026: revenue $241K. The chart follows the revenue to costs, profit and cash.
Microbot Medical: every quarter, Q/Q and Y/Y, holders and guidance →
Microbot Medical’s other material 8-Ks
- Nov 5, 2026 — FDA decisions Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Fu
- Oct 27, 2026 — FDA decisions Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Ro
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.